Product and method for simple freezing and thawing treatment of biological sample

A simplified freeze-thaw method using specific cryoprotectant concentrations in freezing and thawing solutions addresses the complexity of existing methods, enhancing efficiency and reducing errors while maintaining sample viability.

WO2026235205A1PCT designated stage Publication Date: 2026-11-12REPROLIFE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017709
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing freeze-thaw methods for biological samples, particularly using vitrification, require complex operations due to multiple solutions and high operator burden, leading to errors and prolonged processing times.

Method used

A simplified freeze-thaw process using a freezing solution with 10-28% permeable and 100-1500 mmol/L impermeable cryoprotectants, and a thawing solution with 100-700 mmol/L impermeable cryoprotectants, reducing the number of steps and maintaining sample viability.

Benefits of technology

The method significantly reduces the number of steps, minimizes operator burden, prevents errors, and maintains high viability rates for biological samples, allowing direct assisted hatching in the thawing solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

The present disclosure addresses the problem of providing a product and a freezing and thawing method for a freezing and thawing treatment with which it is possible to perform freezing and thawing treatment of a biological sample by means of a simple operation. The present disclosure relates to a product for a freezing and thawing treatment of a biological sample, the product being characterized by combining a freezing solution containing a 10-28% (v / v) permeable cryoprotective agent and a 100-1500 mmol / L impermeable cryoprotective agent, with a thawing agent containing a 100-700 mmol / L impermeable cryoprotective agent. Furthermore, the present disclosure relates to a method for freezing and thawing a biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

Products and methods for simple freeze-thaw processing of biological samples

[0001] The present disclosure relates to a product for freeze-thaw processing of biological samples. The present disclosure further relates to a method for freeze-thaw processing of biological samples using the product of the present disclosure.

[0002] Cryopreservation technology for biological samples is utilized in fields that utilize living cells, tissues, and the like, such as the livestock industry field and the medical field. In the livestock industry field, cryopreservation of animal ova and embryos is utilized for the preservation and mass production of specific species, as well as for controlling the timing of pregnancy in domestic animals.

[0003] In the field of human assisted reproductive technology, cryopreservation technologies for ova and embryos have attracted attention and are used by many people, such as preservation of surplus embryos during in vitro fertilization, fertility preservation for cancer patients, and social oocyte preservation that expands the possibilities for women to become pregnant. In Japan, as of 2021, it is reported that 1 in 11.6 people is a live-born infant resulting from in vitro fertilization (Non-Patent Document 1).

[0004] Furthermore, also in the fields of organ transplantation and regenerative medicine, cryopreservation technology is used for preserving collected and produced cells, tissues, and the like.

[0005] As cryopreservation techniques for biological samples, a slow freezing method and a vitrification freezing method are known. The vitrification freezing method is a method that suppresses ice crystal formation of water by rapid cooling in the presence of a high-concentration organic solvent, causes extremely little damage to cells, and is widely used for cryopreservation of ova and embryos. Freeze-thaw solutions that have been developed to date are very excellent, as they can exhibit a survival rate close to 100% for ova and embryos after freeze-thaw processing. However, existing freeze-thaw processing methods require extremely complicated operations due to the use of a large number of solutions, and have problems such as a heavy burden on operators, occurrence of errors, and prolonged operation time.

[0006] Accordingly, there is a need for a freeze-thaw solution and a freeze-thaw method that can perform freeze-thaw processing of biological samples in a simpler manner.

[0007] "Clinical Implementation Results of In Vitro Fertilization and Embryo Transfer, etc., 2021," [online], Japan Society of Obstetrics and Gynecology, [Accessed April 10, 2024], Internet <URL: https: / / www.jsog.or.jp / activity / art / 2021_JSOG-ART.pdf> David K. Gardner, Ariel Weissman, Colin M. Howles, Zeev Shoham, "TEXTBOOK OF ASSISTED REPRODUCTIVE TECHNIQUES", Vol.1, (USA), CRC Press, 5th edition, 2018, p.280-287 Japanese Society of Clinical Embryologists (supervisor), "ART Standard Practical Lab Manual for Embryologists," Ishiyaku Publishers, July 2023, p.96-113 Magosaburo Kasai, and Tetsunori Mukaida. "Cryopreservation of animal and human embryos by vitrification." Reproductive BioMedicine Online 9.2 (2004), pp. 164-170. Shibahara, Hiroaki (ed.), "Guidelines for the Treatment of Infertility and Recurrent Miscarriage," Chugai Igaku-sha, November 2016, pp. 556-563. Japanese Society of Clinical Embryologists (supervisor), "ART Standard Practical Lab Manual for Embryologists," Ishiyaku Publishers, July 2023, pp. 124-128.

[0008] The object of this disclosure is to provide a product and a method for freeze-thawing that enable the freeze-thawing of biological samples with simple operations.

[0009] The inventors have found that by reducing the content of permeable and impermeable cryoprotective agents in the freezing and thawing solutions, the freeze-thawing process can be simplified without affecting the viability of biological samples.

[0010] A first aspect of the present disclosure is a product for the freeze-thaw treatment of a biological sample, characterized by combining a freezing solution containing 10-28% (v / v) of a permeable cryoprotectant and 100-1500 mmol / L of an impermeable cryoprotectant, and a thawing solution containing 100-700 mmol / L of an impermeable cryoprotectant.

[0011] A second aspect of the present disclosure is a freezing solution for use in the products of the present disclosure.

[0012] A third aspect of the present disclosure is a thawing solution for use in the products of the present disclosure.

[0013] A fourth aspect of the present disclosure is a method for freezing and thawing a biological sample, comprising: (a) immersing the biological sample in a freezing solution containing 10 to 28% (v / v) of a permeable cryoprotectant and 100 to 1500 mmol / L of an impermeable cryoprotectant; (b) freezing the biological sample; and (c) immersing the frozen biological sample in a thawing solution containing 100 to 700 mmol / L of an impermeable cryoprotectant.

[0014] The products and methods disclosed herein enable freeze-thaw processing of biological samples in fewer steps while maintaining a high viability rate in the frozen and thawed solutions, thereby reducing working time, minimizing the burden on workers, and preventing errors. Furthermore, the products and methods disclosed herein can significantly reduce the number of steps up to assisted hatching (described later).

[0015] The following describes embodiments of the product and freeze-thaw method relating to this disclosure, but the product and freeze-thaw method relating to this disclosure are not limited to the embodiments described below.

[0016] 1. Product A first aspect of the Product Disclosure is a product for the freeze-thaw treatment of biological samples, characterized in that the product comprises a combination of a freeze solution and a thaw solution. In the product of the Disclosure, the freeze solution comprises 10 to 28% (v / v) of a permeable cryoprotectant and 100 to 1500 mmol / L of an impermeable cryoprotectant, and the thaw solution comprises 100 to 700 mmol / L of an impermeable cryoprotectant. The product of the Disclosure may further include an equilibrium solution used before the use of the freeze solution. The product of the Disclosure can simplify the freeze-thaw treatment procedure of biological samples by setting the content of the permeable cryoprotectant and impermeable cryoprotectant in the freeze solution and thaw solution, respectively, to specific ranges.

[0017] In this disclosure, “biological sample” means cells, tissues, and mixtures thereof of biological origin. “Biological organism” in this disclosure may include, for example, mammals, reptiles, amphibians, and birds, and is preferably a mammal. Mammals may include, but are not limited to, humans, cattle, horses, dogs, pigs, sheep, goats, and mice, and is preferably humans, cattle, pigs, and mice.

[0018] In this disclosure, examples of biologically derived cells include, but are not limited to, egg cells, sperm cells, fertilized eggs, embryos, ES cells (embryonic stem cells), iPS cells (induced pluripotent stem cells), mesenchymal stem cells, hematopoietic stem cells, neural stem cells, umbilical cord cells and other stem cells, hepatocytes, nerve cells, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, blood cells, tumor cells, and more. Examples of biologically derived tissues include, but are not limited to, ovarian tissue, testicular tissue, skin, nerves, blood vessels, cartilage, and cornea.

[0019] In this disclosure, “freeze-thaw treatment” means a treatment that includes freezing biological tissue and thawing the frozen biological tissue, and mainly refers to vitrification. “Vitrification” is also called “rapid freezing,” and is a method of rapidly freezing the biological tissue in question by immersing it in a solution containing a permeable cryoprotectant and then using liquid nitrogen or the like. The freeze-thaw treatment in this disclosure can be used to preserve the biological tissue in question for a long period of time and to use it when needed.

[0020] The product of this disclosure is characterized by combining a freezing solution and a thawing solution. In this disclosure, "combination" means using the freezing solution of this disclosure for freezing the biological sample and then using the thawing solution of this disclosure in a series of steps for freezing and thawing a biological sample. In other words, "combination" means thawing a biological sample frozen using the freezing solution of this disclosure using the thawing solution of this disclosure. Therefore, the product of this disclosure does not have to be sold as a single kit containing the freezing solution and the thawing solution, as long as it is intended to be used in a series of steps for freezing and thawing a biological sample. For example, it may be sold separately under the same brand name in the form of a kit containing the freezing solution and a kit containing the thawing solution. Furthermore, even if the freezing solution and the thawing solution are sold as separate products, they can still be considered the product of this disclosure if it is intended that a biological sample frozen using the freezing solution of this disclosure is thawed using the thawing solution of this disclosure. Naturally, the form of a single product containing the freezing solution and the thawing solution is also included in the product of this disclosure.

[0021] [Freezing Solution] In this disclosure, “freezing solution” means a solution used for freezing biological samples. The freezing solution in this disclosure comprises 10–28% (v / v) of a permeable cryoprotectant and 100–1500 mmol / L of an impermeable cryoprotectant. By setting the content of the permeable and impermeable cryoprotectants in the freezing solution within this range, the products of this disclosure can simplify the freeze-thaw procedure for biological samples.

[0022] (Permeable Cryoprotective Agents) The freezing solutions of this disclosure include permeable cryoprotective agents. Permeable cryoprotective agents are those that, upon contact with cells or tissues, penetrate the cell membrane and into the intracellular space, protecting the cells or tissues from freezing damage during freezing. In the art, permeable cryoprotective agents are also called "cell membrane permeable (freezing) protectants." Examples of permeable cryoprotective agents include, but are not limited to, polyhydric alcohols (ethylene glycol, propylene glycol, 1,3-propanediol, butanediol, butylene glycol, isoprene glycol, dipropylene glycol, glycerin, etc.), dimethyl sulfoxide (DMSO), acetamide, and are preferably selected from ethylene glycol, propylene glycol, DMSO, and mixtures thereof.

[0023] The content of the permeable cryoprotectant in the freezing solution may be 10% (v / v) or more, 12.5% ​​(v / v) or more, 14% (v / v) or more, or 15% (v / v) or more, relative to the total amount of the freezing solution. Alternatively, the content of the permeable cryoprotectant in the freezing solution may be 28% (v / v) or less, 25% (v / v) or less, 23% (v / v) or less, 21% (v / v) or less, or 20% (v / v) or less, relative to the total amount of the freezing solution. If the freezing solution of this disclosure contains a mixture of two or more compounds as the permeable cryoprotectant, the content of the permeable cryoprotectant means the sum of the content of each compound.

[0024] (Impermeable Cryoprotective Agent) The freezing solution of this disclosure includes an impermeable cryoprotective agent. In the freezing solution of this disclosure, the impermeable cryoprotective agent plays a role in supporting stable intracellular vitrification by increasing the osmotic pressure of the extracellular fluid and promoting dehydration of intracellular water. In the art, impermeable cryoprotective agents are also called "cell membrane impermeable (freezing) protectors." Examples of impermeable cryoprotective agents in this disclosure include, but are not limited to, sugars and polymers. Examples of sugars include monosaccharides, disaccharides, and oligosaccharides such as polysaccharides consisting of 3 to 10 monosaccharides. Examples of monosaccharides include glucose, fructose, and galactose. Examples of disaccharides include sucrose, trehalose, and lactose, and examples of polysaccharides include raffinose. Examples of polymers include Ficol and polyvinylpyrrolidone (PVP). The impermeable cryoprotectant of this disclosure is preferably selected from sucrose, trehalose, and mixtures thereof.

[0025] The content of the impermeable cryoprotectant in the freezing solution may be 100 mmol / L or more, 200 mmol / L or more, 300 mmol / L or more, or 400 mmol / L or more, relative to the total volume of the freezing solution. Alternatively, the content of the impermeable cryoprotectant in the freezing solution may be 1500 mmol / L or less, 1200 mmol / L or less, 1000 mmol / L or less, 900 mmol / L or less, 800 mmol / L or less, or 700 mmol / L or less, relative to the total volume of the freezing solution.

[0026] (Additional Components) The freezing solutions of this disclosure may contain any additional components other than those described above, as long as they are able to exert the effects of the product of this disclosure. Examples of additional components, but not limited to, include serum, serum substitutes, cellular nutrients (inorganic salts, organic salts, sugars, amino acids, vitamins, etc.), cellular physical protective substances (hyaluronic acid, viscosity modifiers), pH buffers, antibiotics, and solution performance confirmation reagents (pH indicators, etc.). Furthermore, if all additional components are heat-resistant, the freezing solutions of this disclosure can be sterilized by autoclaving.

[0027] (Medium) In one embodiment, the frozen solution of the present disclosure may include a medium. Any aqueous solvent can be used as the medium, for example, water. Alternatively, an existing cell culture medium containing each of the components described above can be used as the medium. The medium may be used in powder form and mixed with water. Examples of cell culture media that can be used in the frozen solution of the present disclosure include, but are not limited to, minimal essential medium (MEM), Eagle MEM medium, DMEM medium, CSCM medium, 199 medium (M199), HTF medium, and the like.

[0028] [Thawing Solution] In this disclosure, “thawing solution” means a solution used to thaw a frozen biological sample. The thawing solution in this disclosure contains 100 to 700 mmol / L of an impermeable cryoprotectant. By setting the content of the impermeable cryoprotectant in the thawing solution in this range, the products of this disclosure can simplify the freeze-thaw procedure for biological samples.

[0029] The thawing solution serves to thaw the frozen biological sample and remove permeable cryoprotective agents that have penetrated into the cells during the freezing process. Therefore, in one embodiment, the thawing solution in this disclosure preferably does not contain permeable cryoprotective agents.

[0030] (Impermeable Cryoprotectant) The thawing solution of this disclosure contains an impermeable cryoprotectant. In the thawing solution of this disclosure, the impermeable cryoprotectant plays a role in preventing excessive cell swelling when removing permeable cryoprotectant that has penetrated the cells during thawing. The impermeable cryoprotectant in the thawing solution of this disclosure may be the same as that described in the (Impermeable Cryoprotectant) section of [Freezing Solution]. The impermeable cryoprotectant in the thawing solution may be the same as or different from the impermeable cryoprotectant in the freezing solution, but preferably the impermeable cryoprotectant in the thawing solution is the same as the impermeable cryoprotectant in the freezing solution.

[0031] The content of the impermeable cryoprotectant in the thawing solution may be 100 mmol / L or more, 150 mmol / L or more, or 200 mmol / L or more, relative to the total volume of the thawing solution. Alternatively, the content of the impermeable cryoprotectant in the thawing solution may be 700 mmol / L or less, 600 mmol / L or less, 500 mmol / L or less, or 400 mmol / L or less, relative to the total volume of the thawing solution.

[0032] (Additional Components) The thawing solution of this disclosure may contain any additional components other than impermeable cryoprotectants, as long as they are effective in providing the product of this disclosure. The additional components in the thawing solution may be the same as those described in the (Additional Components) section of the [Freezing Solution]. The additional components in the thawing solution may be the same as or different from the additional components in the freezing solution.

[0033] (Medium) In one embodiment, the thawing solution of the present disclosure may contain a medium. The medium in the thawing solution may be the same as that described in the (Medium) section of the [Freezing Solution]. The medium in the thawing solution may be the same as or different from the medium in the freezing solution.

[0034] [Equilibrium Solution] In one embodiment, the product of the present disclosure may include an equilibrium solution. In the present disclosure, “equilibrium solution” means a solution that serves to permeate a permeable cryoprotectant at a lower concentration than that of the freezing solution into the cells of the biological sample to be frozen, as a pretreatment for treatment with the freezing solution, in order to prevent a rapid change in osmotic pressure. The equilibrium solution in the present disclosure contains 0.1 to 28% (v / v) of a permeable cryoprotectant.

[0035] (Permeable Cryoprotectant) The equilibrium solution of this disclosure contains a permeable cryoprotectant. As the permeable cryoprotectant in the equilibrium solution, the permeable cryoprotectant described in the (Permeable Cryoprotectant) section of [Freezing Solution] can be used. The permeable cryoprotectant in the equilibrium solution may be the same as or different from the permeable cryoprotectant in the freezing solution, but preferably the permeable cryoprotectant in the equilibrium solution is the same as the permeable cryoprotectant in the cryoprotectant.

[0036] The content of the permeable cryoprotectant in the equilibrium solution of this disclosure may be, for example, 0.1% (v / v) or more, 1% (v / v) or more, 5% (v / v) or more, or 10% (v / v) or more, relative to the total amount of the equilibrium solution. Alternatively, the content of the permeable cryoprotectant in the equilibrium solution of this disclosure may be, for example, 28% (v / v) or less, 25% (v / v) or less, 23% (v / v) or less, 21% (v / v) or less, or 20% (v / v) or less, relative to the total amount of the equilibrium solution. If the equilibrium solution of this disclosure contains a mixture of two or more compounds as the permeable cryoprotectant, the content of the permeable cryoprotectant means the sum of the contents of each compound.

[0037] (Additional Components) The equilibrium solution of this disclosure may contain any additional components other than permeable cryoprotectants, as long as they allow the product of this disclosure to exert its effects. The additional components in the equilibrium solution may be the same as those described in the (Additional Components) section of the [Freezing Solution]. The additional components in the equilibrium solution may be the same as or different from the additional components in the freezing solution. Furthermore, if all the additional components are heat-resistant, the freezing solution of this disclosure can be sterilized by autoclaving.

[0038] (Medium) In one embodiment, the equilibrium solution of the present disclosure may contain a medium. The medium in the equilibrium solution may be the same as that described in the (Medium) section of the [Freezing Solution]. The medium in the equilibrium solution may be the same as or different from the medium in the freezing solution.

[0039] [Container] In one embodiment, the freezing solution of the Disclosure may be filled in at least one container. Also in one embodiment, the thawing solution of the Disclosure may be filled in at least one container. The container in the product of the Disclosure may have any shape. For example, the container in the Disclosure may be in the shape of a bottle that can be filled with an amount of freezing or thawing solution equivalent to multiple uses. Alternatively, the container in the Disclosure may be in the shape of a petri dish or a plate having at least one well that can be filled with an amount of freezing or thawing solution equivalent to one use.

[0040] In one embodiment, the container of the present disclosure may be in the shape of a plate having one or more recesses. The recesses may be filled with an amount of freezing solution required for one freezing treatment, or an amount of thawing solution required for one thawing treatment. Furthermore, the container of the present disclosure may be sealed with a peelable lid. In one embodiment, the peelable lid is preferably an easily peelable lid. In one embodiment, the container of the present disclosure may be a single-use container, i.e., a disposable container.

[0041] The container in this disclosure can be any type as long as it does not impair the effects and benefits of the product of this disclosure. Examples of container materials, but not limited to these, include glass, polyethylene, polypropylene, polystyrene, acrylic, cycloolefin polymers, and cyclic olefin copolymers. Furthermore, the container in this disclosure may be composed of a combination of multiple materials. In one embodiment, the container in this disclosure is preferably transparent from the viewpoint of facilitating the freeze-thaw treatment of biological samples.

[0042] (Effects of the product of the present disclosure) The product of the present disclosure sets the permeable cryoprotectant in the freezing solution to 10 to 28% (v / v) and the non-permeable cryoprotectant to 100 to 1500 mmol / L, and sets the non-permeable cryoprotectant in the thawing solution to 100 to 700 mmol / L, whereby the procedure of the freezing and thawing treatment for biological samples can be simplified.

[0043] In the freezing treatment of biological samples, particularly in vitrification treatment, it is necessary to replace the intracellular water with a permeable cryoprotectant to prevent ice crystal formation during freezing. For this reason, conventional freezing solutions are formulated with a permeable cryoprotectant at a level of about 30 to 50% (v / v). Since such a freezing solution has high osmotic pressure, directly immersing a biological sample or the like in the freezing solution causes a large osmotic pressure difference between the inside and outside of the cells, which becomes a cause of physical damage to the cells. Therefore, before immersing in the freezing solution, the biological sample is immersed in an equilibration solution containing a low-concentration permeable cryoprotectant to allow the permeable cryoprotectant to permeate into the cells and increase the intracellular osmotic pressure, followed by immersion in the freezing solution, which required a plurality of steps (Non-Patent Document 2, Non-Patent Document 3).

[0044] In addition, when a biological sample frozen using a high-concentration permeable cryoprotectant is directly immersed in a low-osmotic-pressure solution for thawing, water rapidly permeates from the low-osmotic-pressure thawing solution into the high-osmotic-pressure interior of the cells, which may cause physical damage to the cells. Therefore, in conventional thawing treatments, a plurality of steps are required: first, the biological sample is thawed using a high-osmotic-pressure thawing solution containing a high-concentration non-permeable cryoprotectant, and then sequentially immersed in diluted solutions in which the concentration of the non-permeable cryoprotectant is gradually reduced to return to an isotonic state (Non-Patent Document 2, Non-Patent Document 3).

[0045] While it has been known that freezing biological samples can be performed while suppressing cell damage by using a freezing solution containing 30-50% (v / v) of a permeable cryoprotective agent (Non-Patent Literature 4), there has been insufficient research into reducing the concentration of the permeable cryoprotective agent in the freezing solution. As a result of diligent research by the present inventors, it has become clear that even with a permeable cryoprotective agent concentration of 10-28% (v / v) in the freezing solution, freezing of biological samples can be performed while sufficiently maintaining cell viability. This permeable cryoprotective agent content is significantly lower than the permeable cryoprotective agent content in conventional freezing solutions.

[0046] Because the freezing solution of this disclosure has a lower concentration of permeable cryoprotectant than conventional freezing solutions, it is possible to freeze biological samples without damaging cells even when they are directly immersed in the solution. Therefore, the product of this disclosure can reduce the number of steps in the freezing process compared to conventional methods. Furthermore, since biological samples frozen using such a freezing solution have lower intracellular osmotic pressure compared to conventional methods, they will not be damaged even when directly immersed in a low-osmotic pressure thawing solution during thawing. Therefore, the product of this disclosure can also significantly reduce the number of steps in the thawing process. In this way, the product of this disclosure can greatly reduce the number of steps in the freezing and thawing process of biological samples, resulting in reduced working time, reduced burden on workers, and prevention of errors.

[0047] Furthermore, the product of the present disclosure also has the effect that Assisted Hatching (AHA) can be performed directly in the thawing solution. It is known that freeze-thawed blastomeres are prone to hatching failure because the zona pellucida (the transparent glycoprotein layer surrounding an ovum or blastomere) hardens. AHA is a technique for artificially incising the hardened zona pellucida to assist hatching. AHA is performed by incising the zona pellucida using a laser or the like, and the gap between the zona pellucida and the embryo (inner cell mass) needs to be expanded to prevent damage to the internal embryo. Therefore, when performing AHA, the blastomere that has been returned to an isotonic state after thawing must be immersed in a solution with increased osmotic pressure (AHA solution) using sugars or the like to cause shrinkage (Non-Patent Document 5, Non-Patent Document 6).

[0048] AHA is an operation performed following the thawing treatment of blastomeres, but conventional thawing solutions have high osmotic pressure and cause damage to embryos, so the thawed embryos cannot be immersed for a long time. For this reason, it was necessary to return the thawed embryos to an isotonic state once, then immerse them again in an AHA solution with high osmotic pressure before performing AHA. As described above, in the conventional freeze-thaw treatment, it was necessary to go through a large number of steps from thawing the frozen blastomere to further performing AHA.

[0049] However, since the thawing solution of the present disclosure has a low content of non-permeating cryoprotectant, its osmotic pressure is lower than that of conventional thawing solutions, and it does not cause damage to the embryo even when the embryo is immersed for a long time. Therefore, AHA can be performed directly in the thawing solution. This greatly reduces the number of steps compared with the conventional method in which the embryo is once returned to an isotonic state and then immersed again in the AHA solution to perform AHA. By such reduction of steps, the product of the present disclosure can bring effects such as shortening of operation time, reduction of operator's burden, and prevention of errors.

[0050] Therefore, the products of this disclosure do not have to contain a diluent. Preferably, the products of this disclosure do not contain a diluent. In this disclosure, “diluent” means a solution used after the thawing solution in the thawing process, and is generally characterized by containing an impermeable cryoprotectant at a lower concentration than the thawing solution. In the art, the diluent is sometimes referred to as a “second thawing solution,” a “third thawing solution,” and so on.

[0051] 2. Freezing Solutions for Use in the Products of the Disclosure A second aspect of the Disclosure is a freezing solution for use in the products of the Disclosure. "Freezing solution for use in the products of the Disclosure" means a thawing solution intended to be used as one of the components of the products of the Disclosure, more specifically intended to be used in combination with a thawing solution containing an impermeable cryoprotectant in a concentration of 100 to 700 mmol / L. Thus, "freezing solution for use in the products of the Disclosure" includes freezing solutions before they become products, and freezing solutions sold individually. The description of "freezing solution" is the same as that given in the section on "Freezing Solution" in "1. Products".

[0052] 3. Thawing Solutions for Use in the Products of the Disclosure A third aspect of the Disclosure is a thawing solution for use in the products of the Disclosure. "Thawing solution for use in the products of the Disclosure" means a freezing solution intended to be used as one of the components of the products of the Disclosure, more specifically, a freezing solution intended to be used in combination with a freezing solution containing 10 to 28% (v / v) permeable cryoprotectant and 100 to 1500 mmol / L impermeable cryoprotectant. Accordingly, "thawing solution for use in the products of the Disclosure" includes thawing solutions before they become products, and thawing solutions sold on their own. The description of "thawing solution" is the same as that given in the section "Thawing Solution" of "1. Products".

[0053] 4. Method for Freezing and Thawing Biological Samples A fourth aspect of the present disclosure is a method for freezing and thawing biological samples. The method for freezing and thawing according to the present disclosure includes: (a) immersing a biological sample in a freezing solution containing 10 to 28% (v / v) of a permeable cryoprotectant and 100 to 1500 mmol / L of an impermeable cryoprotectant; (b) freezing the biological sample; and (c) immersing the frozen biological sample in a thawing solution containing 100 to 700 mmol / L of an impermeable cryoprotectant.

[0054] (Step of immersion in freezing solution) The freeze-thaw method of this disclosure includes (a) a step of immersion in a freezing solution containing 10-28% (v / v) of a permeable cryoprotectant and 100-1500 mmol / L of an impermeable cryoprotectant. The description of the freezing solution is the same as that described in the [Freezing Solution] section of "1. Products". Step (a) can be carried out by immersing the biological sample to be frozen in the freezing solution at room temperature. The immersion time of the biological sample in the freezing solution can be 10 minutes or less, 5 minutes or less, or 1 minute or less.

[0055] (Freezing step) The freeze-thaw method of the present disclosure includes a step of freezing the biological sample of step (a). Step (b) is a step of freezing the biological sample that was immersed in the freezing solution in step (a). Freezing of the biological sample can be carried out by any method, but it is preferable to carry out by rapid cooling in order to prevent the formation of ice crystals. Rapid cooling can be carried out, for example, by immersing the biological sample in liquid nitrogen.

[0056] (Thawing step) The freeze-thaw method of the present disclosure includes the step of (c) thawing a frozen biological sample by immersing it in a thawing solution containing 100 to 700 mmol / L of an impermeable cryoprotectant. The description of the thawing solution is the same as that described in the [Thawing Solution] section of "1. Products". Step (c) can be carried out by immersing the biological sample frozen in step (b) in a thawing solution that has been warmed to 37°C in advance. The immersion time in the thawing solution can be, for example, about 1 minute, about 3 minutes, or about 5 minutes.

[0057] (Equilibration Step) In one embodiment, the freeze-thaw method of the present disclosure may further include a step of equilibrating a biological sample by immersing it in an equilibration solution. Step (a0) is a step in which, prior to step (a), the biological sample to be frozen is immersed in an equilibration solution to allow a permeable cryoprotectant to penetrate into the cells. The description of the equilibration solution is the same as the description in the section [Equilibration Solution] of "1. Products". Step (a0) can be carried out, for example, by immersing the biological sample in the equilibration solution at room temperature for 1 to 30 minutes.

[0058] (Step of performing assisted hatching) In one embodiment, the freeze-thaw method of the present disclosure may further include step (d) performing assisted hatching in the thawing solution after step (c). Assisted hatching can be performed by any method known to those skilled in the art. Examples of assisted hatching methods, but not limited to, include laser methods, mechanical methods, and chemical methods. A laser method is a method of thinning or opening a portion of the zona pellucida by irradiating the zona pellucida of the blastocyst with an infrared laser. A mechanical method is a method of inserting a needle-shaped pipette between the zona pellucida and the blastocyst to cut the zona pellucida. A chemical method is a method of thinning the zona pellucida by dissolving the outside of the zona pellucida with a reagent such as acidic Tyrode's solution or pronase reagent.

[0059] (Effects of the freeze-thaw method of this disclosure) The freeze-thaw method of this disclosure, by using a freeze solution containing 10-28% (v / v) of a permeable cryoprotectant and 100-1500 mmol / L of an impermeable cryoprotectant in step (a), and a thaw solution containing 100-700 mmol / L of an impermeable cryoprotectant in step (c), can significantly reduce the number of freeze-thaw steps, thereby resulting in reduced working time, reduced burden on workers, and prevention of errors. Furthermore, it also has the effect of allowing AHA to be performed in the thaw solution.

[0060] The following embodiments will describe the products and freeze-thaw methods of the present disclosure in more detail. However, the products and freeze-thaw methods of the present disclosure are not limited to the following embodiments.

[0061] Example 1 Performance evaluation of the product of the present disclosure using normal bovine blastocysts 1 The performance of the product of the present disclosure was evaluated using normal bovine blastocysts.

[0062] 1. Test Method (1) Preparation of Test Solution A base solution was prepared by adding MEM medium powder, pH adjuster, and antibacterial agent to water and dissolving them. A permeable cryoprotectant (ethylene glycol and DMSO) and an impermeable cryoprotectant (trehalose) were added to the base solution to prepare a freezing solution. The concentration of the permeable cryoprotectant was set to 15-29% (v / v) in total, and the concentration of the impermeable cryoprotectant was set to 500-680 mmol / L. In addition, a thawing solution was prepared by adding an impermeable cryoprotectant (trehalose) to the base solution to a concentration of 270 mmol / L. The content of each component under each test condition is described in detail in Table 1.

[0063] (2) Performance evaluation of the products disclosed herein Tests using bovine blastocysts (Bovine Embryo Assay, BEA) were conducted according to the following procedure: a. Normal vitrified F1 bovine blastocysts (expanded stage (*1)) produced at the Kobe ET Center were thawed and cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and 38.8°C. After culture, only blastocysts that had fully recovered were selected. The number of blastocysts per group was 10. b. The blastocysts were treated with their respective freezing solutions and frozen. c. The frozen blastocysts were treated with a thawing solution and thawed. The thawed blastocysts were cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and 38.8°C. The performance of each product was evaluated by the viability of blastocysts at 0 and 24 hours after thawing, and by the development score at 24 hours.

[0064] *1 The developmental stage was determined as Expanded stage when the zona pellucida thickness was 5 μm and appeared as a single line under a stereomicroscope.

[0065] The survival rate and development score of blastocysts were evaluated as follows: - Survival rate: Blastocysts without apoptosis (instigmatism) of the ICM (inner cell mass) and TE (trophectoderm) were considered viable, and the number of viable blastocysts was shown as a percentage. - Development score: Each viable blastocyst was scored according to the following points. The total score was divided by the total number of viable blastocysts to obtain the score. 0 points: Expanded Stage blastocyst 1 point: Hatching blastocyst 2 points: Post-hatching blastocyst

[0066] 2. Results The results are shown in the table below.

[0067]

[0068] Referring to Table 1, the survival of bovine blastocysts was confirmed 24 hours after thawing under all test conditions, indicating that freezing and thawing bovine blastocysts is possible under all conditions. Furthermore, lower concentrations of permeable cryoprotective agents tended to be associated with better survival rates and developmental scores.

[0069] Example 2 Performance evaluation of the product of the present disclosure using normal bovine blastocysts 2 The performance of the product of the present disclosure, including the equilibrium solution, was evaluated using bovine blastocysts.

[0070] 1. Test Method (1) Preparation of Test Solution A base solution was prepared by adding MEM medium powder, pH adjuster, and antibacterial agent to water and dissolving them. Permeable cryoprotective agents (ethylene glycol and DMSO) and impermeable cryoprotective agents (trehalose) were added to the base solution to prepare equilibrium solution, frozen solution, thawed solution, and diluted solution. The contents of the permeable and impermeable cryoprotective agents are as shown in Tables 2 and 3, respectively.

[0071] (2) Performance evaluation of the product of this disclosure using normal bovine blastocysts Tests using normal bovine blastocysts (Bovine Embryo Assay, BEA) were performed according to the following procedure: a. Vitrified normal F1 bovine blastocysts (expanded stage) produced at the Kobe ET Center were thawed and cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and 38.8°C. After culture, only blastocysts that had fully recovered were selected. The number of blastocysts per group was 5 to 30. b. The blastocysts were treated with equilibrium solution. c. Next, the blastocysts from step b were treated with their respective freezing solutions and frozen. d. The frozen blastocysts were treated with thawing solution and thawed. In the conventional method (C1), they were further treated with a dilution solution. Thawed blastocysts were cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and at 38.8°C. The performance of each product was evaluated by the viability of blastocysts at 0 and 24 hours after thawing, and by the development score at 24 hours. The viability and development score were evaluated using the same method as in Example 1.

[0072] 2. Results The results are shown in the table below.

[0073]

[0074]

[0075] Under conditions other than L2, viable bovine blastocysts were observed 24 hours after thawing, indicating that freezing and thawing bovine blastocysts is possible under any conditions other than L2. Furthermore, developmental scores exceeding 1 were obtained under H2 and M1-M3 conditions, indicating that bovine blastocyst development was progressing without problems.

[0076] Example 3: Investigation of the concentration of impermeable cryoprotective agent in thawing solution. The effect of the concentration of impermeable cryoprotective agent in thawing solution was evaluated using bovine blastocysts.

[0077] 1. Test Method (1) Preparation of Test Solution A base solution was prepared by adding MEM medium powder, pH adjuster, and antibacterial agent to water and dissolving them. Permeable cryoprotective agents (ethylene glycol and DMSO) and impermeable cryoprotective agents (trehalose) were added to the base solution to prepare equilibrium solution, frozen solution, thawed solution, and diluted solution. The contents of the permeable and impermeable cryoprotective agents are as shown in Table 4.

[0078] (2) Evaluation using bovine blastocysts The bovine blastocyst test (Bovine Embryo Assay, BEA) was performed according to the following procedure. a. Vitrified F1 bovine blastocysts (day 8 expanding stage (*2)) produced at the Kobe ET Center were thawed and cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and 38.8°C. After culture, only blastocysts that had fully recovered were selected. The number of blastocysts per group was 5 to 9. b. The blastocysts were treated with equilibrium solution. c. Next, the blastocysts from step b were treated with their respective freezing solutions and frozen. d. The frozen blastocysts were treated with thawing solution and thawed. In the conventional method (C2), they were further treated with a dilution solution. Thawed blastocysts were cultured for 24 hours in SOFF medium, 6% CO2, 6% O2, and at 38.8°C. The performance of each product was evaluated by the viability of blastocysts at 0 and 24 hours after thawing, and by the development score at 24 hours.

[0079] *2 The developmental stages were determined as follows: If the zona pellucida thickness was 5 μm or more and the pellucida appeared as a band-like line under a stereomicroscope, it was determined to be the Expanding Stage. If the zona pellucida thickness was 5 μm or more and the pellucida appeared as a single line under a stereomicroscope, it was determined to be the Expanded Stage.

[0080] The survival rate and development score of blastocysts were evaluated as follows: - Survival rate: Blastocysts without apoptosis (instigmatism) of the ICM (inner cell mass) and TE (trophectoderm) were considered viable, and the number of viable blastocysts was shown as a percentage. - Development score: Each viable blastocyst was scored according to the following points. The total score was divided by the total number of viable blastocysts to obtain the score. 0 points: Expanding Stage blastocyst 1 point: Expanded Stage blastocyst 2 points: Hatching blastocyst 3 points: Post-hatching blastocyst

[0081] 2. Results The results are shown in the table below.

[0082]

[0083] These results demonstrate that even with a concentration of 500 mmol / L of the impermeable cryoprotectant in the thawing solution of this disclosure, the freeze-thaw treatment of bovine blastocysts can be carried out without any problems.

[0084] Example 4: Freeze-thaw treatment test of human oocytes. The performance of the product of this disclosure was compared with that of a conventional method using fresh human oocytes. This test was conducted with the approval of the Ethics Committee of Advanced Fertility Center Cancun.

[0085] 1. Test Method (1) Preparation of Test Solutions Equilibrium solution, freezing solution, thawing solution, and diluted solution were prepared using the same procedure as described in Example 2. The contents of permeable cryoprotectant and impermeable cryoprotectant are as shown in Table 5.

[0086] (2) Preparation of sperm for in vitro fertilization Sperm obtained from donor patients who gave their consent was liquefied on a heated plate at 37°C for 1 hour. The sperm was washed using the Percoll method with Percoll reagent (Fujifilm Corporation) and prepared for in vitro fertilization so that the motile sperm count after purification was 1.2 million / mL. The purified sperm was cultured in an incubator until in vitro fertilization.

[0087] (3) Freezing and Thawing Treatment of Human Oocytes a. Oocyte-cumulus cell complexes (COCs) collected from donor patients who gave their consent were immediately checked for oocyte maturity under a stereomicroscope. Subsequently, cumulus cells were completely removed from the COCs in which maturity was confirmed, and recovery culture was performed for 1 hour using SAGE1-stepmedium (Fujifilm Corporation) (37°C, 5% CO2, 5% O2, 90% N2). b. Next, the oocytes were sequentially treated with equilibrium solution and then with freezing solution and frozen. c. The frozen oocytes were treated with thawing solution and thawed. In comparative example (CE1), further treatment with a diluted solution was performed. After thawing, oocytes without cell membrane breakdown were determined to be viable oocytes and underwent 3 hours of recovery culture for in vitro fertilization (37°C, 5% CO2, 5% O2, 90% N2).

[0088] (4) In vitro fertilization and developmental rate evaluation a. After recovery culture, oocytes without cell membrane breakdown were identified as viable oocytes and used for in vitro fertilization. Sperm prepared in procedure (2) were injected into the viable oocytes, and developmental culture (37°C, 5% CO2, 5% O2, 90% N2) was performed using SAGE1-stepmedium (Fujifilm Corporation). b. Fertilization was confirmed 24 hours after the start of culture. Oocytes in which a secondary polar body and two pronuclei were confirmed were identified as normally fertilized eggs. c. The number of cleavage cells was confirmed and evaluated 48 hours after the start of culture.

[0089]

[0090] These results demonstrate that the method of this disclosure yields fertilization and cleavage rates equivalent to those of the comparative example (conventional method). Therefore, the products and methods of this disclosure demonstrate that they have performance equivalent to conventional methods while reducing the number of freeze-drying steps.

[0091] Example 5: Freeze-thaw treatment test using human blastocysts. The performance of the product of this disclosure was compared with that of a conventional method using human blastocysts. This test was conducted with the approval of the Ethics Committee of Advanced Fertility Center Cancun.

[0092] 1. Test Method (1) Preparation of each solution The equilibrium solution, frozen solution, thawed solution, and diluted solution to be used in the test were prepared using the same method as in Example 2.

[0093] (2) Preparation of sperm for in vitro fertilization Sperm for in vitro fertilization was prepared using the same method as in Example 4.

[0094] (3) Preparation of mature oocytes The oocyte-cumulus cell complex (COC) collected from donor patients who gave their consent was immediately checked under a stereomicroscope for the presence or absence of oocyte maturity. COCs in which oocyte maturity was confirmed were collected and subjected to a 2-hour pre-insemination culture using SAGE1-stepmedium (37°C, 5% CO2, 5% O2, 90% N2).

[0095] (3) Fertilization and Developmental Culture a. 100 μL of SAGE1-stepmedium was dropped into a dish, and one oocyte-cumulus cell complex (COC) was transferred to it. Next, 30 μL of sperm for in vitro fertilization was added, and fertilization was performed. b. The fertilized oocytes were cultured using SAGE1-stepmedium (Fujifilm Corporation) at 37°C, 5% CO2, 5% O2, and 90% N2. After 24 hours from the start of culture, oocytes in which a secondary polar body and two pronuclei were confirmed were identified as fertilized eggs. Embryos that developed into blastocysts on the fifth day after oocyte retrieval were subjected to freeze-thaw treatment.

[0096] (4) Freeze-thaw treatment a. The prepared blastocysts were sequentially treated with equilibrium solution and then freezing solution. b. Next, the frozen blastocysts were treated with thawing solution and thawed. Comparative example (CE2) was further treated with dilution solution. c. The thawed blastocysts were cultured for recovery and development using SEGA1-stepmedium (37°C, 5% CO2, 5% O2, 90% N2). The blastocysts were observed immediately after the start of culture (0 hours), at 3 hours, and at 24 hours, and the survival rate and development score at 24 hours were evaluated. The survival rate and development score were evaluated according to the method described in Example 1.

[0097] 2. Results The results are shown in the table below.

[0098]

[0099] The viability and developmental scores of blastocysts were equivalent in the method of this disclosure and in the comparative example (conventional method). Therefore, it was demonstrated that the products and methods of this disclosure have performance equivalent to conventional methods while reducing the number of freeze-thaw steps.

[0100] The products of this disclosure can be suitably used for the cryopreservation and thawing of biological samples, particularly mammalian fertilized eggs or blastocysts.

[0101] The freeze-thaw method of this disclosure can be suitably used for the cryopreservation and thawing of biological samples, particularly mammalian fertilized eggs or blastocysts.

Claims

1. A product for the freeze-thaw treatment of biological samples, characterized by combining a freezing solution containing 10-28% (v / v) of a permeable cryoprotectant and 100-1500 mmol / L of an impermeable cryoprotectant, and a thawing solution containing 100-700 mmol / L of an impermeable cryoprotectant.

2. The product according to claim 1, further comprising an equilibrium solution containing 0.1 to 28% (v / v) of a permeable cryoprotectant.

3. The product according to claim 1, wherein the permeable cryoprotectant comprises at least one selected from the group consisting of ethylene glycol, propylene glycol, 1,3-propanediol, butanediol, butylene glycol, isoprene glycol, dipropylene glycol, glycerin, dimethyl sulfoxide (DMSO), and acetamide.

4. The product according to claim 1, wherein the impermeable cryoprotectant comprises at least one selected from the group consisting of sugars and polymers.

5. The product according to claim 4, wherein the sugar comprises oligosaccharides.

6. The product according to claim 5, wherein the oligosaccharide comprises at least one selected from the group consisting of glucose, fructose, galactose, trehalose, sucrose, lactose, and raffinose.

7. The product according to claim 4, wherein the polymer comprises at least one selected from the group consisting of Ficol and polyvinylpyrrolidone (PVP).

8. The product according to claim 1, wherein the freezing solution is filled in at least one container.

9. The product according to claim 8, wherein the at least one container comprises at least one recess, the freezing solution is filled in the at least one recess, and the container is sealed with a removable lid.

10. The product according to claim 1, wherein the thawing solution is filled in at least one container.

11. The product according to claim 10, wherein the container comprises at least one recess, the thawing solution is filled in the at least one recess, and the container is sealed with a removable lid.

12. The product according to claim 9 or 11, wherein the peelable lid material is an easy-peel lid material.

13. A freezing solution for use in the product described in claim 1.

14. A thawing solution for use in the product described in claim 1.

15. A method for freezing and thawing a biological sample, comprising: (a) immersing the biological sample in a freezing solution containing 10 to 28% (v / v) of a permeable cryoprotectant and 100 to 1500 mmol / L of an impermeable cryoprotectant; (b) freezing the biological sample from step (a); and (c) thawing the frozen biological sample by immersing it in a thawing solution containing 100 to 700 mmol / L of an impermeable cryoprotectant.

16. The freeze-thaw method according to claim 15, further comprising the step of (a0) immersing the biological sample in an equilibrium solution to equilibrate it, prior to step (a).

17. (d) The freeze-thaw method according to claim 15, further comprising the step of performing assisted hatching in the thawing solution.